Among all the PDE subfamilies, Phosphodiesterase 9 (PDE9) has unique advantages on AD therapy for its highest affinity with cGMP among all the PDE families and its high expression level in the cortex, hippocampus, basal ganglia, and cerebellum of brain.12 Here, ALDH7A1 is linked to Alzheimer disease.